Akers Biosciences(LSE) AKR

Market Cap£50.70M

Since IPON/A

5 YearN/A

1 YearN/A

1 MonthN/A

£6.19

+0.00%

+0.00Today

Akers Biosciences Financials at a Glance

Market Cap

£50.70M

Revenue (TTM)

£0.00

Net Income (TTM)

-£16.57

EPS (TTM)

-£4.34

P/E Ratio

-1.43

Dividend

£0.00

Beta (Volatility)

0.00 (Low)

Dividend

£0.00

Beta (Volatility)

0.00 (Low)

Price

£6.19

Volume

213

Open

£4.04

Price

£6.19

Volume

213

Open

£4.04

Previous Close

£6.19

Daily Range

£0.00 - £0.00

52-Week Range

£4.59 - £6.19

Estimated Earnings Date

N/A

Dividend

£0.00

Beta (Volatility)

0.00 (Low)

Price

£6.19

Volume

213

Open

£4.04

Previous Close

£6.19

Daily Range

£0.00 - £0.00

52-Week Range

£4.59 - £6.19

Estimated Earnings Date

N/A

AKR News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Akers Biosciences

MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which engages in the development of drug products targeting aging, age-related, and autoimmune diseases, chronic pain, anxiety, and sleep disorders. It focuses on developing and commercializing the MyMD-1 and SUPERA-CBD therapeutic platforms. MyMD-1 is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune diseases. Supera-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in Baltimore, MD.

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

CEO

Christopher C. Chapman, Jr., MD

Website

www.qctechnologies.com

AKR Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-108.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-69.93%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

£50.70M

Shares Outstanding

8.19M

Volume

213

Avg. Volume

4.72K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Akers Biosciences Performance Analysis

Akers Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	GBP 0	N/A
2023	2023-12-31	GBP 0	N/A
2024	2024-12-31	GBP 0	N/A
2025	2025-12-31	GBP 0	N/A

Akers Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	GBP -1,174.26	-54.1%
2023	2023-12-31	GBP -532.80	-54.6%
2024	2024-12-31	GBP -1,114.54	109.2%
2025	2025-12-31	GBP -8.66	-99.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

£0.00

N/A

Gross Profit

-£0.01

N/A

Gross Margin

N/A

Market Cap

£50.70M

N/A

Market Cap/Employee

£16.20

N/A

Employees

+1.5%

Net Income

-£6.62

+3.7%

EBITDA

-£3.61

+1.9%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

£0.68

+227.0%

Total Debt

£0.37

N/A

Accounts Receivable

N/A

Inventory

£0.00

N/A

Long Term Debt

£0.23

N/A

Short Term Debt

£0.15

N/A

Return on Assets

-82.79%

+2.6%

Return on Invested Capital

-93.16%

N/A

Free Cash Flow

-£1.96

+1.0%

Operating Cash Flow

-£1.82

+0.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,684.24-0.00%

^DJIDJI

^DJIDJI$53,254.61-0.01%

^IXICNASDAQ

^IXICNASDAQ$26,319.55-0.00%

BTCBitcoin

BTCBitcoin$78,890.00-0.00%

SPCXSPCX

SPCXSPCX$142.81+0.01%

AAPLAAPL

AAPLAAPL$315.25-0.01%

AMZNAMZN

AMZNAMZN$258.45-0.03%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$13.27-0.20%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

CNHCNH Industrial

CNHCNH Industrial$11.83+0.01%

NUNu Holdings

NUNu Holdings$14.55+0.02%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.43-0.02%

Questions About AKR

What is the current price of Akers Biosciences?

Akers Biosciences is trading at £6.19 per share.

What is the 52-week range for Akers Biosciences?

Over the past 52 weeks, Akers Biosciences has traded between £4.59 and £6.19.

How much debt does Akers Biosciences have?

As of the most recent reporting period, Akers Biosciences reported total debt of £371.17K.

How much cash does Akers Biosciences have on hand?

Akers Biosciences reported £307.61K in cash and cash equivalents in its most recent financial results.

What is Akers Biosciences’s dividend yield?

Akers Biosciences does not currently have a dividend yield.

Akers Biosciences(LSE) AKR

Akers Biosciences Financials at a Glance

AKR News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Akers Biosciences

AKR Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Akers Biosciences Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About AKR

What is the current price of Akers Biosciences?

What is the 52-week range for Akers Biosciences?

How much debt does Akers Biosciences have?

How much cash does Akers Biosciences have on hand?

What is Akers Biosciences’s dividend yield?

Premium Investing Services